MedTrace Logo

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

NCT01069809 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2017-01-24

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the individuals are both taking antiretroviral therapy (ART) medication and interrupting ART medication.

Conditions

  • HIV Infection

Interventions

BIOLOGICAL

AGS-004

HIV-1 Immune Therapy

BIOLOGICAL

Placebo

Inactive Placebo Injection

Sponsors & Collaborators

  • Argos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jeffery Jacobson, MD · Drexel University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-08-31
Completion
2015-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01069809 on ClinicalTrials.gov